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Glucaric acid as an indicator of use of 
enzyme-inducing drugs 
The usefulness of urinary glucaric acid determinations to measure enzyme induction by drugs 
was investigated by correlating its excretion rate with the daily drug regimen of 100 
hospitalized patients. The urinary excretion of glucaric acid was higher in patients than in 
normal controls. Patients treated with enzyme inducers excreted more glucaric acid than 
patients not getting them, as well as more than normal controls. In patients on multiple-drug 
therapy, the effect of small doses of known enzyme inducers was masked, but even here 
relatively high doses of potent inducers significantly increased glucaric acid excretion. The 
results also suggest that urinary excretion of glucaric acid may have value as an indicator 
of the use of certain drugs by patients when such information is not revealed by the history. 
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Induction of the liver microsomal hy-
droxylating enzymes by drugs and environ-
mental chemicals is well known in labora-
tory animals. G The influence of enzyme 
induction on human drug-metabolizing 
capacity is less well documented. Little is 
known of the extent of this phenomenon 
in hospitalized and multiple-drug-treated 
patients, probably because methods to 
investigate enzyme induction in man are 
limited. The activity of drug-metabolizing 
enzymes has been assayed in liver speci-
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mens obtained during abdominal surgery2 
and in needle biopsy samples. 20 The latter 
technique is contraindicated in most acute 
cases; the former an uncommon opportu-
nity. 
The disappearance rate of test drugs19 
does not necessarily reflect the total activity 
of drug-hydroxylating enzyme in patients 
on multiple-drug therapy4, 22 because these 
drugs may compete with the test drugs for 
the same metabolizing enzyme system. H , 20 
Genetic differences in human drug me-
tabolism also complicate the interpretation 
of drug disappearance rates. 2G , 27 The uri-
nary excretion of glucaric acid, a product 
in the glucuronic acid pathway of several 
species of animals as well as man,S, 1" 
parallels the activity of drug-hydroxylating 
enzymes," c" G, 28 which provides a con-
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venient approach for detection of enzyme 
induction in man. 9 - 11 The present investi-
gation was undertaken to study the ability 
of glucaric acid determination to reflect 
drug-inducing therapy of hospitalized 
patients. 
Material and methods 
Subjects. The 100 subjects investigated, 
aged 18 to 80 years, were divided into 
three patient groups. The first group, 
under treatment in the Clinical Research 
Unit (CRU) of the University of Michigan 
Hospital, had the following categories of 
disease: endocrinologic (17), cardiovascu-
lar (11), collagen diseases (8), and gastro-
intestinal (5). The second group, consist-
ing of 41 predominantly acutely ill pa-
tients at St. Joseph Mercy Hospital 
(SJMH), Ann Arbor, Michigan, had car-
diovascular (27), endocrinologic (5), and 
other diseases (9). Eighteen recipients of 
kidney transplants 'at the University of 
Michigan Hospital formed the third pa-
tient group, and 24 normal volunteers, 
aged 26 to 44 years, under no continuous 
medication, served as controls. 
The drug regimen of all the patients was 
recorded daily. The previous medication of 
the patients treated in the CRU had been 
unchanged at least 2 weeks prior to admis-
sion. All patients had normal liver function 
tests. The serum creatinine values were 
normal, except the transplant recipients 
who had elevated serum creatinines at 
the beginning of the investigation. Food 
consumption of the patients was not re-
stricted. 
Methods. The 24 hour urine collections 
were as follows: Patients in CRU, daily 
after admission for up to 3 weeks; trans-
plant recipients, daily for up to 4 weeks 
after operation; and patients in SJMH, 
daily 5 to 7 days after admission. If the 
samples were not analyzed directly after 
the collection, they were stored at -20 0 C. 
Glucaric acid (GA) in the urine was 
determined as described by Marsh.1s 
Briefly, urinary GA was converted to D-
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glucaro-l,4-lactone at 100° C and pH 2, 
and the specific inhibition of (:I-glucuroni-
dase (rat liver preparation) by the latter 
compound was determined by measuring 
the hydrolysis of phenolphthalein glucuro-
nide ( Sigma, St. Louis) . Urine samples 
heat-treated at pH 8 were used as controls. 
The difference in absorbance at 540 nm of 
urine samples heat-treated at acidic and 
alkaline pH, respectively, was read from a 
standard curve, obtained by plotting per 
cent enzyme inhibition against various con-
centrations of the standard, D-gIucaro-l,4-
lactone (Sigma). The excretion of glucaric 
acid is expressed as ,umoles of glucaro-l,4-
lactone per 24 hours. If necessary, urine 
samples were diluted or concentrated, to 
produce about 50% inhibition of the enzy-
matic reaction. 
The following drugs and classes of drugs 
were considered to be enzyme inducers: 
barbiturates, antihistamines, cortisone, 
prednisone, phenylbutazone, and mitotane 
(o,p'-DDD). The statistical treatment of 
the data included the Student's t test, the 
paired sample t test, and the F test. 
Results 
Drug therapy and glucaric acid excre-
tion. The excretion of GA in the 41 pa-
tients (CRU) investigated after their ad-
mission averaged 19.4 ± 12.0 ,umoles as 
compared to 13.9 ± 4.9 ,umoles of the con-
trols. The difference (p < 0.05) and the 
variance in this group (p < 0.005) were 
significant. Fig. 1 shows the GA excretion 
in these patients in reference to previous 
drug therapy. GA excretion of patients 
treated with inducers was Significantly 
higher than that of other patients and 
of the controls. The mean values of GA 
excretion of patients treated with nonin-
ducers and those receiving no medication 
did not differ from the control group. 
Glucaric acid excretion during hospital 
treatment. Urinary GA excretion of 6 nor-
mal people was followed for 1 week. The 
excretion rate in these subjects ranged 
from 5 to 25 ,umoles per day, with an indi-
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Fig. 1. Glucaric acid excretion (mean ± S.D.) in admitted patients and in normal individuals. 
The patients are grouped on the basis of previous drug therapy. 
vidual standard deviation of ± 1.5 to 3.0 
f-Lmoles. The GA excretion in hospitalized 
patients was dependent on the drugs taken 
and is illustrated by the following case 
reports. 
Patient 1. The excretion of GA increased 
rapidly in a 38-year-old woman with Cush-
ing's syndrome after beginning therapy 
with o,p'-DDD (Fig. 2, A). 
Patient 2. A daily decrease of GA excre-
tion was noted in a 36-year-old man with 
celiac disease after his second admission, 
although no drugs were prescribed to this 
patient following his previous discharge 
from the hospital. However, the patient 
eventually admitted using "sleeping pills" 
at home (Fig. 2, B). 
Patient 3. In a 47-year-old man with 
numerous medical problems the urinary 
excretion of GA decreased during the three 
days following his admission during which 
time the intake of barbiturates and anal-
getics were restricted. When these drugs 
were again administered the excretion of 
GA increased, followed by a decrease dur-
ing a period of food restriction. After the 
resumption of a normal diet, the excretion 
of GA again increased (Fig. 2, C). 
Patients 4, 5, and 6. The GA excretion 
varied within the normal limits in 3 female 
patients (aged 42, 43, and 50) with chronic 
rheumatic disease. During the investiga-
tion period, drug regimens of these pa-
tients were unchanged (Fig. 2, D). 
Fasting and glucaric acid excretion. 
Table I. Effect of fasting on glucaric 
acid excretion 
Glucaric acid 
(/lmoles glucaro-
1,4-lactone) 
Mean 
± S.D. 
n 
Before 
26.2 
16.3 
8 
Fasting (days) 
1[ 2 
18.9~ 14.P 
13.9 10.6 
8 8 
"Decrease significant (p < 0.01); paired sample t 
test. 
Eight patients (Table I) fasted for 2 days. 
During that time, the GA excretion of 
these subjects Significantly decreased be-
low that before the food restriction. 
Multiple-drug therapy and glucaric acid 
excretion. In 41 patients investigated dur-
ing hospitalization (SJMH), the GA excre-
tion averaged 37.6 ± 23.1 f-Lmoles (Fig. 3). 
The difference between the mean GA ex-
cretion of these patients and that obtained 
in the control group (p < 0.001) and the 
variance in these two groups (p < 0.001) 
were Significant. The hospitalized patients 
received multiple-drug therapy (5 ± 2 
drugs per day). Ten patients of this group 
received enzyme inducers (phenobarbital 
25 mg per day, 2 cases; diphenhydramine 
50 mg per day, 6 cases; prednisone 20 mg 
per day, 2 cases). GA excretion by these 
10 averaged 38.9 ± 27.6 f-Lmoles, while in 
the other patients of this group who re-
ceived only noninducers it averaged 35.3 ± 
21.5. This difference is not statistically 
significant. 
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Fig. 2. A-D, The excretion of glucaric acid in hospitalized patients: jncreased excretion after 
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therapy (D). 
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Glucaric acid excretion in recipients of 
kidney transplants. GA excretion in 18 pa-
tients after kidney transplantation is shown 
in Fig. 4. Five patients receiving anti-
convulsants (100 to 300 mg diphenyl-
hydantoin alone or in combination with 
100 to 200 mg phenobarbital) excreted 
more (p < 0.001) glucaric acid during the 
postoperative phase than the remaining 13 
in the group. The additional drug therapy 
for all of the 18 patients was similar: im-
munosuppressive drugs (azathioprine and 
prednisone), antibiotics, analgetics, and 
occasionally cathartics and tranquilizers. 
Thc GA excretion in this group was high-
est during I to 3 days following the opera-
tion and decreased thereafter. This de-
crease was significant in the 5 patients on 
anticonvulsants (p < 0.01) but not in the 
others. 
The urinary creatinine excretion in the 
5 patients on anticonvulsants did not diHer 
from that of others in this group. 
Discussion 
Marked individual diHerences in blood 
levels of drugs in patients treated in the 
same way have been reported for a num-
ber of compounds known to be metabolized 
by liver microsomes. 1 :l Little is known 
about drug metabolism in hospitalized pa-
tients. 18 Our results suggest that urinary 
glucariC acid determination is a reliable 
indicator of enzyme induction in patients. 
Our data show greater variation in GA 
excretion in drug-taking patients than in 
normals, suggesting considerable diHer-
ences in their drug-metabolizing capacity. 
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Fig. 3. Glucaric acid excretion (mean ± S.D.) in 
hospitalized patients on multiple-dmg therapy and 
in normal controls. 
Glucaric acid determinations also detected 
the use of inducers by patients withhold-
ing information on drug use. 
Drug metabolism in acutely ill patients 
as well as the eHects of repeated doses of 
drug mixtures on the human drug-metabo-
lizing capacity have not been systemati-
cally investigated. There is some evidence 
suggesting that hospitalization itself may 
stimulate drug metabolism in patients on 
therapy known to inhibit metabolizing 
cnzymes."4 Our results show increased GA 
excretion in patients on multiple-drug ther-
apy and a daily variation of GA excretion 
in patients on alternating-drug therapy. 
Changes in human conditions, e.g., preg-
nancy or malignancy, may aHect the GA 
excretion. 'G 
The evidence suggests that if glucariC 
acid determination is to be used as an 
indicator of enzyme induction in acutely 
ill patients, it must be made on serial 24 
hour urine specimens. If the use of induc-
ing drugs has to be elicited by a single 
determination in patients with unknown 
medical history, only 80 ,umoles per day or 
more of GA can be taken as substantial 
evidence (Fig. 5). The amount of drugs 
required to induce liver enzymes in man 
is not known nor is the response similar 
in all patients. Our data show that in 
multiple-drug treatment the eHect of small 
doses of inducers on GA excretion may 
be masked, but in higher doses, such as 
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Fig. 4. Glucaric acid excretion (mean ± S.D.) in 
recipients of kidney transplants after operation 
and in normal controls. 
those of anticonvulsants capable of pre-
venting convulsions, GA excretion is sig-
nificantly increased. 
Investigations in experimental animals 
have revealed both impairment and en-
hancement of drug metabolism during 
starvation. 7,12 During fasting the produc-
tion of glucuronides may be decreased 
without any impairment in the activity of 
enzymes involved in this pathwayY It is 
therefore likely that the decreased GA 
excretion in our patients undergoing short-
term fasting reflects a lack of substrate in 
the biosynthetic pathway of GA. 
The decreasing GA excretion in renal 
transplant patients, especially in those on 
anticonvulsants, probably reflects the effect 
of immunosuppressive drugs on the activity 
of GA-producing enzymes.3 The present 
findings agree with our previous investiga-
tions,21, 23 which also revealed the impor-
tance of the sum effect of all drugs when 
evaluating enzyme induction in patients 
receiving many of them at the same time. 
4" 
2" 
,. 
Clinical Pharmacology 
and Therapeutics 
Ildlcers il 
larll doses 
illIJ C ••• il,d Drl, nann 
111.1' ildlC,rs Ildlurs il 
s.all doses 
F::::::3 II .. · ildlcer alII' 
E;;:::l aid 
lIor.11 1111' 
Fig. 5. Significance of a single determination of 
glucaric acid in a patient with unknown medical 
history. 
It must be emphasized that increased or 
decreased GA excretion rates do not neces-
sarily express the actual capacity of the 
liver to metabolize a drug given later. In 
evaluating GA determinations, the general 
treatment of the patient has to be con-
sidered. Since urinary GA is an end prod-
uct of the glucuronic acid pathway, lim-
ited availability of corresponding sub-
strates in a restricted diet can alter the 
level of GA excretion. Patients are often 
treated simultaneously with inducing as 
well as enzyme-inhibiting drugs and, since 
net effect of all these compounds deter-
mines the activity of the drug-metaboliz-
ing enzyme system, in some such caSes GA 
excretion may be in normal range. Al-
though elevated excretion rates suggest the 
use of enzyme-inducing drugs, such values 
need not necessarily correlate with an 
enhanced disappearance rate of a drug 
given later. The inducers still present in 
the body may inhibit the metabolism of a 
subsequently administered drug. Our re-
cent studies in multiple-drug-treated rats 
support this view.2G 
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